Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
33.56
+0.09 (0.27%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Agios Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 98.34 | 54.03 | 36.5 | 26.82 | 14.24 | - | |
Revenue Growth | 140.58% | 48.03% | 36.07% | 88.36% | - | - |
Cost of Revenue | 364.63 | 345.88 | 305.45 | 298.41 | 281.61 | 256.97 |
Gross Profit | -266.29 | -291.85 | -268.95 | -271.58 | -267.37 | -256.97 |
Selling, General & Admin | 192.74 | 180.28 | 156.78 | 119.9 | 121.67 | 121.45 |
Operating Expenses | 192.74 | 180.28 | 156.78 | 119.9 | 121.67 | 121.45 |
Operating Income | -459.02 | -472.13 | -425.74 | -391.49 | -389.05 | -378.42 |
Interest & Investment Income | 46.3 | 56.38 | 48.08 | 33.34 | 12.79 | 0.84 |
Other Non Operating Income (Expenses) | 0.42 | 1.96 | 6.49 | 6.06 | 16.6 | 21.07 |
EBT Excluding Unusual Items | -412.3 | -413.8 | -371.17 | -352.09 | -359.65 | -356.51 |
Gain (Loss) on Sale of Assets | - | - | 200 | - | - | - |
Other Unusual Items | - | - | 889.14 | - | 127.85 | - |
Pretax Income | -412.3 | -413.8 | 717.97 | -352.09 | -231.8 | -356.51 |
Income Tax Expense | -1.02 | -1.02 | 44.24 | - | - | - |
Earnings From Continuing Operations | -411.29 | -412.78 | 673.73 | -352.09 | -231.8 | -356.51 |
Earnings From Discontinued Operations | - | - | - | - | - | 1,961 |
Net Income | -411.29 | -412.78 | 673.73 | -352.09 | -231.8 | 1,605 |
Net Income to Common | -411.29 | -412.78 | 673.73 | -352.09 | -231.8 | 1,605 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 59 | 58 | 57 | 56 | 55 | 60 |
Shares Outstanding (Diluted) | 59 | 58 | 58 | 56 | 55 | 60 |
Shares Change | 0.43% | 0.14% | 4.02% | 1.57% | -9.36% | -12.39% |
EPS (Basic) | -7.01 | -7.12 | 11.86 | -6.33 | -4.23 | 26.55 |
EPS (Diluted) | -7.01 | -7.12 | 11.64 | -6.33 | -4.23 | 26.55 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -365.25 | -377.29 | -391.53 | -297.06 | -314.36 | -413.06 |
Free Cash Flow Per Share | -6.22 | -6.51 | -6.76 | -5.34 | -5.74 | -6.83 |
Gross Margin | -270.79% | - | - | - | - | - |
Operating Margin | -466.78% | -873.87% | -1166.47% | -1459.52% | -2732.07% | - |
Profit Margin | -418.24% | -764.01% | 1845.92% | -1312.63% | -1627.82% | - |
Free Cash Flow Margin | -371.42% | -698.33% | -1072.73% | -1107.49% | -2207.58% | - |
EBITDA | -453.67 | -466.96 | -420.08 | -384.86 | -380.48 | -369.18 |
D&A For EBITDA | 5.35 | 5.18 | 5.65 | 6.62 | 8.56 | 9.24 |
EBIT | -459.02 | -472.13 | -425.74 | -391.49 | -389.05 | -378.42 |
Effective Tax Rate | - | - | 6.16% | - | - | - |
Revenue as Reported | 98.34 | 54.03 | 36.5 | 26.82 | 14.24 | - |